Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

A Quick Take On Metsera, Inc. Metsera, Inc. (NASDAQ:MTSR) has filed to raise $275 million in an IPO of its common stock, according to SEC S-1/A registration information. The firm is a clinical ...

Investing.com -- Metsera, a clinical-stage biotechnology ... The initial public offering (IPO) consisted of 15,277,778 shares ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is ...

The offering is entirely comprised of shares offered by Metsera, which could signal that existing investors are not participating in the IPO, potentially raising concerns about their confidence in ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. The New York-based company has yet to set expectations on the size of its ...

Metsera (NASDAQ:MTSR) was able to complete its initial public offering [IPO] back on February 3rd of 2025. Before taking expenses into account, it was able to generate net proceeds of about $316.2 ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside.

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

Additionally, Metsera is accelerating its oral formulation program for MET-097o, with outcomes anticipated in late 2025. The recent $316 million IPO will support operations through 2027 as the ...